Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Clara Fehrmann"'
Autor:
Fernando Carvalho Neuenschwander, Ofra Barnett-Griness, Stefania Piconi, Yasmin Maor, Eduardo Sprinz, Nimer Assy, Oleg Khmelnitskiy, Nikita V. Lomakin, Boris Mikhailovich Goloshchekin, Ewelina Nahorecka, Adilson Joaquim Westheimer Calvacante, Anastasia Ivanova, Sergey Vladimirovich Zhuravel, Galina Yurevna Trufanova, Stefano Bonora, Amer Saffoury, Ami Mayo, Yury G. Shvarts, Giuliano Rizzardini, Rogerio Sobroza de Mello, Janaina Pilau, Alexey Klinov, Benjamin Valente-Acosta, Oleg Olegovich Burlaka, Natalia Bakhtina, Maskit Bar-Meir, Ivan Nikolaevich Shishimorov, Jose Oñate-Gutierrez, Cristian Iván García Rincón, Tatiana Ivanovna Martynenko, Ludhmila Abrahão Hajjar, Ana Carolina Nazare de Mendonca Procopio, Krzysztof Simon, Walter Gabriel Chaves Santiago, Adam Fronczak, Conrado Roberto Hoffmann Filho, Osama Hussein, Vladimir Aleksandrovich Martynov, Guido Chichino, Piotr Blewaska, Jacek Wroblewski, Sergio Saul Irizar Santana, Andres Felipe Ocampo Agudelo, Adam Barczyk, Rachael lask Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Michal Klein, Clara Fehrmann, Gina Eagle, Vered Katz Ben-Yair, Mark L. Levitt
Publikováno v:
Microorganisms, Vol 12, Iss 9, p 1767 (2024)
Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral treatment under investigation being evaluated for treatment of hospitalized patients with severe COVID-19 pneumonia. A
Externí odkaz:
https://doaj.org/article/4abee192ba974c30b03ccb75515ad1f3
Autor:
David Y. Graham, Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M. Scott Harris, Shuhong Zhao, Ira N. Kalfus
Publikováno v:
Antibiotics, Vol 13, Iss 8, p 694 (2024)
This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting Mycobacterium avium subspecies paratuberculosis (MAP), long considered a putative cause, would favorably affect Cro
Externí odkaz:
https://doaj.org/article/e2493f4da86e452f9ac5eb4e6ef7ff2d
Autor:
Terry F Plasse, Belkis Delgado, Jeffrey Potts, Danielle Abramson, Clara Fehrmann, Reza Fathi, Grace A McComsey
Publikováno v:
International Journal of Infectious Diseases, Vol 128, Iss , Pp 148-156 (2023)
Objectives: We performed a pilot study of upamostat, a serine protease inhibitor, in outpatients with symptomatic COVID-19 before a pivotal trial. Methods: SARS-CoV-2 patients with ≥2 moderate-severe symptoms onset within 5 days were randomized to
Externí odkaz:
https://doaj.org/article/d6b8d059fd41475e8822d724894bbf91
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Pneumonia
Autor:
Fernando Carvalho Neuenschwander, Ofra Barnett-Griness, Stefania Piconi, Yasmin Maor, Eduardo Sprinz, Nimer Assy, Oleg Khmelnitskiy, Nikita Lomakin, Boris Mikhailovich Goloshchekin, Ewelina Nahorecka, Adilson Joaquim Westheimer Calvacante, Anastasia Ivanova, Sergey Vladimirovich Zhuravel, Galina Yurevna Trufanova, Stefano Bonora, Amer Saffoury, Ami Mayo, Yury Shvarts, Giuliano Rizzardini, Rogerio Sobroza de Mello, Janaina Pilau, Alexey Klinov, Benjamin Valente-Acosta, Oleg Olegovich Burlaka, Natalia Bakhtina, Maskit Bar-Meir, Ivan Nikolaevich Shishimorov, Jose Oñate-Gutierrez, Cristian Ivan Garcia Rincon, Tatiana Ivanovna Martynenko, Ludhmila Abrahão Hajjar, Ana Carolina Nazare de Mendonca Procopio, Krzystof Simon, Walter Gabriel Chaves Santiago, Adam Fronczak, Conrado Roberto Hoffmann Filho, Osama Hussein, Vladimir Aleksandrovich Martynov, Guido Chichino, Piotr Blewaska, Jacek Wroblewski, Sergio Saul Irizar Santana, Andres Felipe Ocampo Agudelo, Adam Barczyk, Rachael L. Gerlach, Eppie Campbell, Aida Bibliowicz, Reza Fathi, Patricia Anderson, Gilead Raday, Michal Klein, Clara Fehrmann, Gina Eagle, Vered Katz Ben-Yair, Mark L. Levitt
RationaleThere are few treatment options for severe COVID-19 pneumonia. Opaganib is an oral treatment under investigation.ObjectiveEvaluate opaganib treatment in hospitalized patients with severe COVID-19 pneumonia.MethodsA randomized, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac5a8655eb260c38557cc88d09eaf63c
https://doi.org/10.1101/2022.06.12.22276088
https://doi.org/10.1101/2022.06.12.22276088
Autor:
Thomas Welton, Patrick Laughlin Mclean, Elliot Offman, Clara Fehrmann, M. Scott Harris, Beata Stępień, Ira N. Kalfus, Grażyna Rydzewska, Tomasz Arlukowicz, Reza Fathi, Robert Hardi, Aida Bibliowicz, Anna Wos, Saleh A. Naser, David Y. Graham, Patricia Anderson, Nastya Kassir
Publikováno v:
American Journal of Gastroenterology. 114:S376-S377
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7388dca0d3cab526fd2454067878d79c
https://doi.org/10.14309/01.ajg.0000592108.53051.68
https://doi.org/10.14309/01.ajg.0000592108.53051.68